Conversely, in the HER2-negative cohort, which is different from the HER2-positive arm for the biology of the tumor, the NC treatment, and also for the immune profile at diagnosis [13], we observed changes in IL-1α, IL-1β, IL-2, IL-6, and GM-CSF levels already at week 12 of ED treatment. The gene discussed is ERBB2; the disease is neoplasm.